Oncology company Oxford BioTherapeutics has announced that the first patient has been dosed in a phase 1b trial investigating its lead candidate OBT076, in patients with Adenoid Cystic Carcinoma (ACC) of the head and neck.
Related Keywords
France , Switzerland , Belgium , Oxford Biotherapeutics , Christian Rohlff , Jean Bourhis , Oncologie Radioth , Lausanne University Hospital , Adenoid Cystic Carcinoma , Professor Jean Bourhis , Bio Developments , Dancer , Ncology , Clinical Trial ,
comparemela.com © 2020. All Rights Reserved.